Tieshi Zhu: NHANES Study Reveals Significant Mortality Risk With Clopidogrel Monotherapy After PCI
Platelets Journal shared an insightful post on LinkedIn:
“How does clopidogrel monotherapy compare to aspirin after PCI and DAPT?
Building on a recent Korean study that highlighted the efficacy of clopidogrel monotherapy following percutaneous coronary intervention (PCI) and standard dual antiplatelet therapy (DAPT), Zhu et al. (2025) conducted a retrospective analysis of the U.S. NHANES 1999–2018 cohort to compare all-cause mortality between clopidogrel and aspirin monotherapy under similar conditions.
Contrary to previous findings in Asian populations, the authors found that clopidogrel monotherapy was associated with increased risks of all-cause mortality, cardiac mortality, and stroke compared to aspirin monotherapy.”
Read the full article here:
Article: Clopidogrel monotherapy is associated with higher mortality risk compared to aspirin: a retrospective analysis of NHANES 1999–2018
Authors: Tieshi Zhu, Yong He, Yuzhang Bei, Hui Mai, and Le Zhao
Follow the newest developments in clotting science with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies